Key Takeaways
- Record quarter with margin leap: Highest-ever quarterly revenue drove EBITDA margin up 251 bps to 15.2% and PAT up 68% YoY, powered by cost optimisation, product mix and capacity utilisation.
- Ibuprofen demand has stabilised: Destocking that depressed volumes for 3–4 quarters is complete; demand normalised from October 2025 and management expects the current level to hold for 4–6 quarters.
- Non-Ibuprofen pharma is the growth engine: Paracetamol, Metformin, Clopidogrel, Pantoprazole and the newly launched Minoxidil all saw improved demand, with non-Ibu exports to regulated markets targeted at 25% of revenue in FY27.
- A large greenfield bet is now live: 100 acres acquired near Bhatinda Highway, environmental clearance obtained, with a phased ₹1,200–₹1,400 crore capex plan funded entirely from internal accruals over 4–5 years.
- What to watch next quarter: Whether the promised 15% top-line growth and 14–14.5% EBITDA margin for FY27 hold through global raw-material and logistics volatility, and any named new product launches from the pipeline.
Quarterly Performance & Profitability Drivers
- Revenue: Q4 FY26 was the highest-ever quarterly revenue, driven by cost optimisation, improving product mix and enhanced capacity utilisation across key product lines.
- Gross margin: The improvement was not a one-off inventory gain; it came from operational efficiencies, good traction in non-Ibuprofen, Ibuprofen performance, capacity utilisation, and a small uptick in finished goods prices in the later part of the quarter. Raw material prices also rose, so abnormal gain from price movements is limited.
- Capacity utilisation: Existing products ran at 85–95%; Paracetamol enhanced capacity at 55%; chemicals at 98–100% even after a capacity increase.
- Employee expense: The rise from ~₹35–40 crores to ~₹70 crores was mainly due to variable pay provided this year and new plants coming up; no substantial change beyond this is expected, with employee costs guided at 9–10% of revenue.
- Pricing: Prices increased across all products (chemicals and API) due to global disturbances, logistics problems and raw material price increases; the effect was concentrated in the later part of March. Spreads are more or less the same or slightly increased because price increases are adjusted into finished product.
Singh: "The change what has been in this quarter is the uptick in the prices and because we were having all volume, so little bit uptick in prices resulting into those numbers. But inventory, I don't think that we were having any meaningful inventory gain in that quarter because the uptick, I think, was in later part of the quarter."
Ibuprofen: Stabilisation & Outlook
- The destocking cycle: Demand was lower 3–4 quarters ago due to overstocking in 2023–2024 and the entry of a new peer. Destocking completed and demand stabilised from October 2025 onwards.
- Demand sustainability: Management anticipates the current demand level will maintain for the upcoming four to six quarters.
- Growth still possible: There is still scope for improving capacity and the export market for Ibuprofen, so some growth is expected even from this mature product.
- Competitive position: When asked about competitor margin concerns, management stated Ibuprofen remains one of IOL's best products, as witnessed by capacity utilisation levels over the last few quarters.
Singh: "No, not at all. I don't know what they are feeling or their concerns are. But regarding the IOL, this is one of the best product, and that is witnessed by the capacity utilizations we are doing now and for last few quarters."
Non-Ibuprofen Pharma & Product Pipeline
- Current traction: Paracetamol, Metformin, Clopidogrel, Pantoprazole and other APIs saw improved demand across markets. The non-Ibu segment was strengthened by the Minoxidil launch and Pantoprazole capacity expansion during the quarter.
- Product potential: Clopidogrel, Pantoprazole and Fenofibrate each have potential of around ₹100–150 crores in the upcoming two years, unlike commodity products like Paracetamol and Metformin which are high-volume.
- Paracetamol ramp: The new fully automated plant is at 55% capacity utilisation; management expects to reach 70–75% in FY27 and full utilisation by FY28. Higher utilisation will result in lower cost of production.
- Exports to regulated markets: Non-Ibuprofen exports to Europe started two years back and are increasing yearly; the target is around 25% exports to regulated markets in FY27, with focus on increasing the 20% export share into developing countries, mainly Europe.
- Regulatory approvals: U.S. FDA has already made two inspections; all products are CEP approved; Metformin was approved by U.S. FDA, followed by Fenofibrate; two or three products' ANDAs are filed with questions replied. The company also has approval from Brazil.
- Pipeline opacity: Management says the company has a "very great pipeline" but normally announces products only when it decides to go ahead; when asked about exciting products to launch this year, the answer was "I think we can expect" without naming any.
Chemical Business & Integration
- Strong quarter: The chemical business delivered strong performance with improvement in both realisation and profitability, supported by stable demand conditions and operational efficiencies.
- Ethyl acetate: Spreads improved by ~$40–$50 per ton, contributed by higher capacity utilisation at the enhanced level and margin expansion from higher ethyl acetate prices.
- Triacetin commissioning: Recently commissioned, Triacetin provides technological and supply chain advantages internally, has wide applications across food, pharma, cosmetics, perfumery and cigarette filters, and can serve as an import substitute.
- Capacity enhancements: Capacity was enhanced in ethyl acetate and acetic anhydride, and together with Triacetin, these moves strengthened integration and supply chain efficiencies.
Greenfield Expansion & Capital Allocation
- Land acquisition: 100 acres acquired near Bhatinda Highway; environmental clearance obtained, other regulatory approvals underway. Plant boundary creation and infrastructure work has begun.
- Timeline: Management is hopeful of securing most approvals in the next three to four months and starting work there. All projects will come up over the next four to five years in a gradual, phased manner.
- Capex plan: Annual capex of ₹200–₹250 crores; total outlay of ₹1,200–₹1,400 crores, funded entirely through internal accruals.
- No buyback: Management was explicit that funds will be utilised for enhancing growth projects; buyback is perhaps the second option while growth projects exist.
Singh: "If we start buying back, then growth will be impacted. you know that we also come up with another land of 100 acres. we also need to invest therein. So the funds majorly will be utilized for the enhancing the growth, we have many growth projects. So till the time we have growth projects, I think buyback perhaps may be the second option."
Raw Material, Supply Chain & External Risks
- Raw material supply disruption: In the first week of March, the company faced crude-based chemical and gas supply issues from government refineries; within one week, pro-rata allocation metrics were developed and there was no difficulty except that one week.
- Crude oil impact: Crude oil price impact has caused raw material prices to go up across the board; logistics costs have also gone up with some global delays, but there has been no major direct impact so far.
- API demand tailwind: API demand from India keeps increasing on a regular basis; reduced investment by European countries in API over the last few years is contributing to demand increase for India.
- Quarterly unpredictability: Management repeatedly stressed that quarter-to-quarter predictions are complicated and risky given global dynamism, and that investors should gauge performance on a yearly basis.
Singh: "it will be better if we gauge the company's performance on the yearly basis rather than the quarterly basis because so much dynamism is happening across the globe. So this is risky to comment on coming quarter or next quarter."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15% top-line growth (may be 1–2% more or less); targeting ~₹2,700 crores | FY27 |
| EBITDA margin | 14% to 14.5% on annual terms | FY27 |
| Ibuprofen demand | Current stabilised demand level to sustain | Next 4–6 quarters |
| Paracetamol capacity utilisation | Rise from 55% to 70–75% | FY27 |
| Paracetamol full utilisation | Full capacity utilisation | FY28 |
| Non-Ibuprofen exports to regulated markets | ~25% export share | FY27 |
| Greenfield approvals | Most approvals secured, work begins | Next 3–4 months |
| Greenfield project completion | All projects phased in | Next 4–5 years |
| Greenfield annual capex | ₹200–₹250 crores per year; total ₹1,200–₹1,400 crores, internally funded | Over project life |
| Employee expense | ~9–10% of revenue | Ongoing |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹619 cr, +17.4% YoY |
| Full-year revenue FY26 | ₹2,319 cr, +11.5% YoY |
| EBITDA | ₹94 cr, +40% YoY |
| EBITDA margin | 15.2%, improved 251 bps YoY |
| Full-year EBITDA margin FY26 | 12.4%, vs 10.7% in FY25 |
| Profit after tax | ₹53 cr, +68% YoY |
| PAT margin | 8.6%, improved 262 bps YoY |
| Full-year PAT FY26 | ₹138 cr, +36% YoY |
| FY27 revenue growth guidance | ~15% (mid to high teens) |
| FY27 EBITDA margin guidance | 14% to 14.5% |
| Capex incurred FY26 | ~₹160 cr, funded entirely through internal accruals |
| Greenfield total outlay | ₹1,200 cr to ₹1,400 cr, over 4–5 years |
| Ibuprofen share of pharma revenue | 62% this quarter |
| Non-ibuprofen share of pharma revenue | 38% this quarter |
| Ibuprofen capacity utilisation | 90% to 95% |
| Paracetamol capacity utilisation | 55% of enhanced 10,800 MT capacity |
| Chemical segment capacity utilisation | 98% to 100% (acetic anhydride and ethyl acetate) |
| Non-ibuprofen exports target FY27 | ~25% of non-ibuprofen revenue |
| R&D spend | 2% to 3% of revenue annually |
| Inventory | ₹371 cr |
| Employee benefit expenses | 9% to 10% of revenue |